Welcome to LookChem.com Sign In|Join Free
  • or
(S)-1-benzyloxy-3-(tert-butyldimethylsilanyloxy)propan-2-ol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

127744-29-0

Post Buying Request

127744-29-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

127744-29-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 127744-29-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,7,7,4 and 4 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 127744-29:
(8*1)+(7*2)+(6*7)+(5*7)+(4*4)+(3*4)+(2*2)+(1*9)=140
140 % 10 = 0
So 127744-29-0 is a valid CAS Registry Number.

127744-29-0Relevant academic research and scientific papers

Biosynthesis of archaebacterial ether lipids. Formation of ether linkages by prenyltransferases

Zhang, Donglu,Dale Poulter

, p. 1270 - 1277 (1993)

Biosynthesis of (R)-2,3-di-Ophytanylglycerol (1), the core lipid of the membranes in the strict anaerobe Methanobacterium thermoautotrophicum, was studied in cell-free preparations. Two prenyltransferase activities were separated by ultracentrifugation. T

Investigating the Individual Importance of the Pam2Cys Ester Motifs on TLR2 Activity

Brimble, Margaret A.,Dunbar, P. Rod,Kelch, Inken D.,Li, Freda F.,Lu, Benjamin L.,Williams, Geoffrey M.

, p. 5415 - 5423 (2021/10/25)

TLR2 agonists are at the forefront of vaccine research for a plethora of diseases, in particular they offer a promising tool for the treatment of cancer. A detailed knowledge of their structure–activity relationship informs the methodical design of vaccin

IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE

-

Page/Page column 157, (2020/05/26)

Provided herein is a conjugate for modulating a natural killer cell or myeloid cell, comprising a targeting moiety and an immunomodulating polynucleotide. Also provided herein is a pharmaceutical composition for modulating a natural killer cell or myeloid cell, comprising a conjugate comprising a targeting moiety and an immunomodulating polynucleotide, and a pharmaceutically acceptable excipient. Additionally provided herein are methods of their use for modulating a natural killer cell or myeloid cell and treating a proliferative disease.

POLYNUCLEOTIDE CONSTRUCTS

-

Page/Page column 75; 76, (2018/03/09)

Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical^ enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE

-

Paragraph 1134, (2018/11/21)

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid

Gajewiak, Joanna,Tsukahara, Ryoko,Fujiwara, Yuko,Tigyi, Gabor,Prestwich, Glenn D.

supporting information; experimental part, p. 1111 - 1114 (2009/04/07)

An efficient enantioselective synthesis of sn-2-aminooxy (AO) analogues of lysophosphatidic acid (LPA) that possess palmitoyl and oleoyl acyl chains Is presented. Both sn-2-AO LPA analogues are agonists for the LPA1, LPA2, and LPAsu

SYNTHESIS OF(2R) AND (2S)-BENZYL-2,3-EPOXYPROPYL ETHER FROM A COMMON PRECURSOR: O-BENZYL-L-SERINE

Witt, P. De,Misiti, D.,Zappia, G.

, p. 5505 - 5506 (2007/10/02)

The (2R) and (2S)-benzyl-epoxypropyl ether are obtained from commercially available O-benzyl-serine, via nitrosation and Mitsunobu reactions to afford the chiral precursors of the above epoxy ethers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 127744-29-0